Kidney Transplantation Under FK 506

Thomas E. Starzl, John Fung, Mark Jordan, Ron Shapiro, Andreas Tzakis, Jerry McCauley, James Johnston, Yuichi Iwaki, Ashokkumar Jain, Mario Alessiani, Satoru Todo

Research output: Contribution to journalArticle

165 Citations (Scopus)

Abstract

The experimental immunosuppressive drug FK 506 was given to 36 renal transplant recipients, many of whom were highly sensitized. Ten were undergoing kidney retransplantation, 10 also underwent liver transplantation at an earlier time (6 patients) or concomitantly (4 patients), and 2 patients received a third organ (heart or pancreas) in addition to a liver and kidney. With follow-ups of 4 to 13 months, all but 2 of the 36 patients are alive, 29 (81%) are dialysis free, and most have good renal function. Twenty of the 29 dialysis-free patients are receiving no or low-dose (2.5 to 5.0 mg/d) prednisone therapy. Only one kidney was lost to cellular rejection. However, patients who had antidonor cytotoxic antibodies in current or historical serum samples had a high rate (3 of 9) of irreversible humoral rejection. A low incidence of posttransplant hypertension was noteworthy. Hirsutism and gingival hyperplasia were not observed. Serum cholesterol levels in patients who took FK 506 were unexpectedly low, and the effect on the level of uric acid was minimal. The side effects of FK 506 therapy include nephrotoxicity, neurotoxicity, and potential induction of a diabetic state. These are similar to the side effects of cyclosporine use, but probably less severe. The seeming safety, efficacy, and relative freedom from side effects of FK 506 encourage further trials in kidney transplantation.

Original languageEnglish (US)
Pages (from-to)63-67
Number of pages5
JournalJAMA: The Journal of the American Medical Association
Volume264
Issue number1
DOIs
StatePublished - Jul 4 1990

Fingerprint

Tacrolimus
Kidney Transplantation
Kidney
Dialysis
Gingival Hyperplasia
Hirsutism
Immunosuppressive Agents
Prednisone
Uric Acid
Serum
Liver Transplantation
Cyclosporine
Pancreas
Cholesterol
Hypertension
Safety
Antibodies
Liver
Incidence
Therapeutics

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Starzl, T. E., Fung, J., Jordan, M., Shapiro, R., Tzakis, A., McCauley, J., ... Todo, S. (1990). Kidney Transplantation Under FK 506. JAMA: The Journal of the American Medical Association, 264(1), 63-67. https://doi.org/10.1001/jama.1990.03450010067032
Starzl, Thomas E. ; Fung, John ; Jordan, Mark ; Shapiro, Ron ; Tzakis, Andreas ; McCauley, Jerry ; Johnston, James ; Iwaki, Yuichi ; Jain, Ashokkumar ; Alessiani, Mario ; Todo, Satoru. / Kidney Transplantation Under FK 506. In: JAMA: The Journal of the American Medical Association. 1990 ; Vol. 264, No. 1. pp. 63-67.
@article{e41122c2b4f34838b0f054a2b94d7a78,
title = "Kidney Transplantation Under FK 506",
abstract = "The experimental immunosuppressive drug FK 506 was given to 36 renal transplant recipients, many of whom were highly sensitized. Ten were undergoing kidney retransplantation, 10 also underwent liver transplantation at an earlier time (6 patients) or concomitantly (4 patients), and 2 patients received a third organ (heart or pancreas) in addition to a liver and kidney. With follow-ups of 4 to 13 months, all but 2 of the 36 patients are alive, 29 (81{\%}) are dialysis free, and most have good renal function. Twenty of the 29 dialysis-free patients are receiving no or low-dose (2.5 to 5.0 mg/d) prednisone therapy. Only one kidney was lost to cellular rejection. However, patients who had antidonor cytotoxic antibodies in current or historical serum samples had a high rate (3 of 9) of irreversible humoral rejection. A low incidence of posttransplant hypertension was noteworthy. Hirsutism and gingival hyperplasia were not observed. Serum cholesterol levels in patients who took FK 506 were unexpectedly low, and the effect on the level of uric acid was minimal. The side effects of FK 506 therapy include nephrotoxicity, neurotoxicity, and potential induction of a diabetic state. These are similar to the side effects of cyclosporine use, but probably less severe. The seeming safety, efficacy, and relative freedom from side effects of FK 506 encourage further trials in kidney transplantation.",
author = "Starzl, {Thomas E.} and John Fung and Mark Jordan and Ron Shapiro and Andreas Tzakis and Jerry McCauley and James Johnston and Yuichi Iwaki and Ashokkumar Jain and Mario Alessiani and Satoru Todo",
year = "1990",
month = "7",
day = "4",
doi = "10.1001/jama.1990.03450010067032",
language = "English (US)",
volume = "264",
pages = "63--67",
journal = "JAMA - Journal of the American Medical Association",
issn = "0002-9955",
publisher = "American Medical Association",
number = "1",

}

Starzl, TE, Fung, J, Jordan, M, Shapiro, R, Tzakis, A, McCauley, J, Johnston, J, Iwaki, Y, Jain, A, Alessiani, M & Todo, S 1990, 'Kidney Transplantation Under FK 506', JAMA: The Journal of the American Medical Association, vol. 264, no. 1, pp. 63-67. https://doi.org/10.1001/jama.1990.03450010067032

Kidney Transplantation Under FK 506. / Starzl, Thomas E.; Fung, John; Jordan, Mark; Shapiro, Ron; Tzakis, Andreas; McCauley, Jerry; Johnston, James; Iwaki, Yuichi; Jain, Ashokkumar; Alessiani, Mario; Todo, Satoru.

In: JAMA: The Journal of the American Medical Association, Vol. 264, No. 1, 04.07.1990, p. 63-67.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Kidney Transplantation Under FK 506

AU - Starzl, Thomas E.

AU - Fung, John

AU - Jordan, Mark

AU - Shapiro, Ron

AU - Tzakis, Andreas

AU - McCauley, Jerry

AU - Johnston, James

AU - Iwaki, Yuichi

AU - Jain, Ashokkumar

AU - Alessiani, Mario

AU - Todo, Satoru

PY - 1990/7/4

Y1 - 1990/7/4

N2 - The experimental immunosuppressive drug FK 506 was given to 36 renal transplant recipients, many of whom were highly sensitized. Ten were undergoing kidney retransplantation, 10 also underwent liver transplantation at an earlier time (6 patients) or concomitantly (4 patients), and 2 patients received a third organ (heart or pancreas) in addition to a liver and kidney. With follow-ups of 4 to 13 months, all but 2 of the 36 patients are alive, 29 (81%) are dialysis free, and most have good renal function. Twenty of the 29 dialysis-free patients are receiving no or low-dose (2.5 to 5.0 mg/d) prednisone therapy. Only one kidney was lost to cellular rejection. However, patients who had antidonor cytotoxic antibodies in current or historical serum samples had a high rate (3 of 9) of irreversible humoral rejection. A low incidence of posttransplant hypertension was noteworthy. Hirsutism and gingival hyperplasia were not observed. Serum cholesterol levels in patients who took FK 506 were unexpectedly low, and the effect on the level of uric acid was minimal. The side effects of FK 506 therapy include nephrotoxicity, neurotoxicity, and potential induction of a diabetic state. These are similar to the side effects of cyclosporine use, but probably less severe. The seeming safety, efficacy, and relative freedom from side effects of FK 506 encourage further trials in kidney transplantation.

AB - The experimental immunosuppressive drug FK 506 was given to 36 renal transplant recipients, many of whom were highly sensitized. Ten were undergoing kidney retransplantation, 10 also underwent liver transplantation at an earlier time (6 patients) or concomitantly (4 patients), and 2 patients received a third organ (heart or pancreas) in addition to a liver and kidney. With follow-ups of 4 to 13 months, all but 2 of the 36 patients are alive, 29 (81%) are dialysis free, and most have good renal function. Twenty of the 29 dialysis-free patients are receiving no or low-dose (2.5 to 5.0 mg/d) prednisone therapy. Only one kidney was lost to cellular rejection. However, patients who had antidonor cytotoxic antibodies in current or historical serum samples had a high rate (3 of 9) of irreversible humoral rejection. A low incidence of posttransplant hypertension was noteworthy. Hirsutism and gingival hyperplasia were not observed. Serum cholesterol levels in patients who took FK 506 were unexpectedly low, and the effect on the level of uric acid was minimal. The side effects of FK 506 therapy include nephrotoxicity, neurotoxicity, and potential induction of a diabetic state. These are similar to the side effects of cyclosporine use, but probably less severe. The seeming safety, efficacy, and relative freedom from side effects of FK 506 encourage further trials in kidney transplantation.

UR - http://www.scopus.com/inward/record.url?scp=0025286343&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025286343&partnerID=8YFLogxK

U2 - 10.1001/jama.1990.03450010067032

DO - 10.1001/jama.1990.03450010067032

M3 - Article

VL - 264

SP - 63

EP - 67

JO - JAMA - Journal of the American Medical Association

JF - JAMA - Journal of the American Medical Association

SN - 0002-9955

IS - 1

ER -

Starzl TE, Fung J, Jordan M, Shapiro R, Tzakis A, McCauley J et al. Kidney Transplantation Under FK 506. JAMA: The Journal of the American Medical Association. 1990 Jul 4;264(1):63-67. https://doi.org/10.1001/jama.1990.03450010067032